000291690 001__ 291690
000291690 005__ 20250123112130.0
000291690 0247_ $$2doi$$a10.18632/oncotarget.28527
000291690 0247_ $$2pmid$$apmid:39018218
000291690 037__ $$aDKFZ-2024-01494
000291690 041__ $$aEnglish
000291690 082__ $$a610
000291690 1001_ $$0P:(DE-HGF)0$$aZhang, Yiyao$$b0$$eFirst author
000291690 245__ $$aCorrection: Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.
000291690 260__ $$a[Erscheinungsort nicht ermittelbar]$$bImpact Journals LLC$$c2024
000291690 3367_ $$2DRIVER$$aarticle
000291690 3367_ $$2DataCite$$aOutput Types/Journal article
000291690 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1737627653_4292$$xErratum/Correction
000291690 3367_ $$2BibTeX$$aARTICLE
000291690 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000291690 3367_ $$00$$2EndNote$$aJournal Article
000291690 500__ $$aOriginal article: Oncotarget. 2015; 6:9999–10015. https://doi.org/10.18632/oncotarget.3171
000291690 536__ $$0G:(DE-HGF)POF4-319H$$a319H - Addenda (POF4-319H)$$cPOF4-319H$$fPOF IV$$x0
000291690 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo02.dkfz.de
000291690 650_7 $$2NLM Chemicals$$aGemcitabine
000291690 650_7 $$00W860991D6$$2NLM Chemicals$$aDeoxycytidine
000291690 650_7 $$0R16CO5Y76E$$2NLM Chemicals$$aAspirin
000291690 650_7 $$2NLM Chemicals$$aAntimetabolites, Antineoplastic
000291690 650_2 $$2MeSH$$aHumans
000291690 650_2 $$2MeSH$$aGemcitabine
000291690 650_2 $$2MeSH$$aDeoxycytidine: analogs & derivatives
000291690 650_2 $$2MeSH$$aDeoxycytidine: pharmacology
000291690 650_2 $$2MeSH$$aDeoxycytidine: therapeutic use
000291690 650_2 $$2MeSH$$aPancreatic Neoplasms: drug therapy
000291690 650_2 $$2MeSH$$aPancreatic Neoplasms: pathology
000291690 650_2 $$2MeSH$$aPancreatic Neoplasms: metabolism
000291690 650_2 $$2MeSH$$aDrug Resistance, Neoplasm: drug effects
000291690 650_2 $$2MeSH$$aAspirin: pharmacology
000291690 650_2 $$2MeSH$$aAspirin: therapeutic use
000291690 650_2 $$2MeSH$$aNeoplastic Stem Cells: drug effects
000291690 650_2 $$2MeSH$$aNeoplastic Stem Cells: pathology
000291690 650_2 $$2MeSH$$aNeoplastic Stem Cells: metabolism
000291690 650_2 $$2MeSH$$aAntimetabolites, Antineoplastic: pharmacology
000291690 7001_ $$0P:(DE-He78)0144e4bf6eab6053de5a445069012063$$aLiu, Lizhen$$b1
000291690 7001_ $$0P:(DE-HGF)0$$aFan, Pei$$b2
000291690 7001_ $$0P:(DE-He78)bf58bfc5eb550025e7f1f64520b68feb$$aBauer, Nathalie$$b3
000291690 7001_ $$0P:(DE-HGF)0$$aGladkich, Jury$$b4
000291690 7001_ $$aRyschich, Eduard$$b5
000291690 7001_ $$aBazhin, Alexandr V$$b6
000291690 7001_ $$aGiese, Nathalia A$$b7
000291690 7001_ $$aStrobel, Oliver$$b8
000291690 7001_ $$aHackert, Thilo$$b9
000291690 7001_ $$aHinz, Ulf$$b10
000291690 7001_ $$0P:(DE-He78)d39b542b3a0da04c8892923daf9e5794$$aGross, Matthias Wolfgang$$b11
000291690 7001_ $$aFortunato, Franco$$b12
000291690 7001_ $$0P:(DE-HGF)0$$aHerr, Ingrid$$b13$$eLast author
000291690 773__ $$0PERI:(DE-600)2560162-3$$a10.18632/oncotarget.28527$$gVol. 15, no. 1, p. 504 - 506$$n1$$p504 - 506$$tOncoTarget$$v15$$x1949-2553$$y2024
000291690 909CO $$ooai:inrepo02.dkfz.de:291690$$pVDB
000291690 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000291690 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)0144e4bf6eab6053de5a445069012063$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000291690 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000291690 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bf58bfc5eb550025e7f1f64520b68feb$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000291690 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b4$$kDKFZ
000291690 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)d39b542b3a0da04c8892923daf9e5794$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000291690 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-HGF)0$$aDeutsches Krebsforschungszentrum$$b13$$kDKFZ
000291690 9131_ $$0G:(DE-HGF)POF4-319H$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vAddenda$$x0
000291690 9141_ $$y2024
000291690 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-29
000291690 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-29
000291690 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-29
000291690 9202_ $$0I:(DE-He78)G403-20160331$$kG403$$lMolekulare Onkochirurgie$$x0
000291690 9201_ $$0I:(DE-He78)G403-20160331$$kG403$$lMolekulare Onkochirurgie$$x0
000291690 9200_ $$0I:(DE-He78)G403-20160331$$kG403$$lMolekulare Onkochirurgie$$x0
000291690 980__ $$ajournal
000291690 980__ $$aVDB
000291690 980__ $$aI:(DE-He78)G403-20160331
000291690 980__ $$aUNRESTRICTED